Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Inventory (2016 - 2025)

Historic Inventory for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to $16.3 million.

  • Anika Therapeutics' Inventory fell 5890.89% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 5890.89%. This contributed to the annual value of $23.8 million for FY2024, which is 253.4% down from last year.
  • Latest data reveals that Anika Therapeutics reported Inventory of $16.3 million as of Q3 2025, which was down 5890.89% from $16.9 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Inventory ranged from a high of $51.5 million in Q2 2024 and a low of $16.3 million during Q3 2025
  • For the 5-year period, Anika Therapeutics' Inventory averaged around $35.5 million, with its median value being $37.2 million (2022).
  • As far as peak fluctuations go, Anika Therapeutics' Inventory surged by 2079.62% in 2024, and later tumbled by 6711.88% in 2025.
  • Over the past 5 years, Anika Therapeutics' Inventory (Quarter) stood at $36.0 million in 2021, then grew by 10.43% to $39.8 million in 2022, then crashed by 38.57% to $24.4 million in 2023, then decreased by 2.53% to $23.8 million in 2024, then plummeted by 31.61% to $16.3 million in 2025.
  • Its Inventory was $16.3 million in Q3 2025, compared to $16.9 million in Q2 2025 and $21.3 million in Q1 2025.